We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs ("MAIA"), announced today that it has appointed Joseph F. McGuire as Chief Financial Officer.
MAIA Biotechnology, Inc., today announced that it has appointed Mihail Obrocea, M.D., as Chief Medical Officer and Head of Development, and Charlotte Tsou as an independent member of its board of directors.